Research progress on thrombocytopenia induced by ado-trastuzumab emtansine in breast cancer patients
10.3760/cma.j.cn114015-20230728-00565
- VernacularTitle:恩美曲妥珠单抗致乳腺癌患者血小板减少症的研究进展
- Author:
Heqing YUAN
1
;
Lu GAO
1
;
Xiying SHAO
1
Author Information
1. 浙江中医药大学第二临床医学院/浙江省肿瘤医院乳腺内科，杭州 310000
- Publication Type:Journal Article
- Keywords:
Ado-trastuzumab emtansine;
Breast neoplasms;
Neoadjuvant therapy;
Thrombocytopenia
- From:
Adverse Drug Reactions Journal
2024;26(4):238-243
- CountryChina
- Language:Chinese
-
Abstract:
Ado-trastuzumab emtansine (T-DM1) is a conjugate of trastuzumab and emtansine, which is one of the options for adjuvant therapy of residual invasive lesions after neoadjuvant therapy and rescue treatment of advanced breast cancer in patients with human epidermal growth factor receprot 2(HER2) mutation. Thrombocytopenia is one of the common adverse reactions of T-DM1. The incidence of all grade of thrombocytopenia was 3.6%-38.2%, and the incidence of grade 3 and above of thrombocytopenia was 0.4%-14.3% during treatment. The risk of thrombocytopenia is higher in Asian populations, patients with prior therapy of platinum, and those with a baseline platelet count of ≤200×10 9/L. The mechanism of thrombocytopenia caused by T-DM1 is not clear. Attention should be paid to monitoring platelet count during treatment, and patients with thrombocytopenia should be treated according to the severity.
